BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 18096477)

  • 1. Early screening for antibody-mediated rejection in heart transplant recipients.
    Kfoury AG; Hammond ME; Snow GL; Stehlik J; Reid BB; Long JW; Gilbert EM; Bader FM; Bull DA; Renlund DG
    J Heart Lung Transplant; 2007 Dec; 26(12):1264-9. PubMed ID: 18096477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation.
    Kfoury AG; Renlund DG; Snow GL; Stehlik J; Folsom JW; Fisher PW; Reid BB; Clayson SE; Gilbert EM; Everitt MD; Bader FM; Singhal AK; Hammond ME
    J Heart Lung Transplant; 2009 Jan; 28(1):51-7. PubMed ID: 19134531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation.
    Kfoury AG; Snow GL; Budge D; Alharethi RA; Stehlik J; Everitt MD; Miller DV; Drakos SG; Reid BB; Revelo MP; Gilbert EM; Selzman CH; Bader FM; Connelly JJ; Hammond ME
    J Heart Lung Transplant; 2012 Jan; 31(1):46-51. PubMed ID: 22153551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.
    Kfoury AG; Hammond ME; Snow GL; Drakos SG; Stehlik J; Fisher PW; Reid BB; Everitt MD; Bader FM; Renlund DG
    J Heart Lung Transplant; 2009 Aug; 28(8):781-4. PubMed ID: 19632573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns.
    Kfoury AG; Stehlik J; Renlund DG; Snow G; Seaman JT; Gilbert EM; Stringham JS; Long JW; Hammond ME
    J Heart Lung Transplant; 2006 Nov; 25(11):1277-82. PubMed ID: 17097489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant.
    Everitt MD; Hammond ME; Snow GL; Stehlik J; Revelo MP; Miller DV; Kaza AK; Budge D; Alharethi R; Molina KM; Kfoury AG
    J Heart Lung Transplant; 2012 Jul; 31(7):686-93. PubMed ID: 22551931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability and usefulness of immunofluorescence in heart transplantation.
    Bonnaud EN; Lewis NP; Masek MA; Billingham ME
    J Heart Lung Transplant; 1995; 14(1 Pt 1):163-71. PubMed ID: 7727465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
    Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
    Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies.
    Hammond ME; Stehlik J; Snow G; Renlund DG; Seaman J; Dabbas B; Gilbert EM; Stringham JC; Long JW; Kfoury AG;
    J Heart Lung Transplant; 2005 Dec; 24(12):2015-21. PubMed ID: 16364843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis between survivors and nonsurvivors with antibody mediated cardiac allograft rejection.
    Gonzalez-Stawinski GV; Cook DJ; Chui J; Gupta S; Navia JL; Hoercher K; Taylor DO; Yamani MH; Starling RC; Smedira NG
    J Surg Res; 2007 Oct; 142(2):233-8. PubMed ID: 17727888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reclassification of C4d-Positive Endomyocardial Biopsy (EMB) According to New International Society for Heart and Lung Transplantation (ISHLT) 2013 Categories for Reporting Pathologic Antibody-Mediated Rejection (pAMR): Preliminary Data from a Polish Single-Center Study.
    Szymańska S; Grajkowska W; Sobieszczańska-Małek M; Zieliński T; Pronicki M
    Ann Transplant; 2015 Jun; 20():351-6. PubMed ID: 26101425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry staining of C4d to diagnose antibody-mediated rejection in cardiac transplantation.
    Fedson SE; Daniel SS; Husain AN
    J Heart Lung Transplant; 2008 Apr; 27(4):372-9. PubMed ID: 18374872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C4d analysis in endomyocardial biopsies of heart transplant patients: is there a correlation with hemodynamic data?
    Boffini M; Ricci D; Bonato R; Ribezzo M; Simonato E; Saviolo R; Checco L; Comoglio C; Rinaldi M
    Transplant Proc; 2011 May; 43(4):1168-70. PubMed ID: 21620080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C4d deposition in cardiac allografts correlates with alloantibody.
    Smith RN; Brousaides N; Grazette L; Saidman S; Semigran M; Disalvo T; Madsen J; Dec GW; Perez-Atayde AR; Collins AB
    J Heart Lung Transplant; 2005 Sep; 24(9):1202-10. PubMed ID: 16143234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of surveillance biopsies in infant heart transplant recipients.
    Balzer DT; Moorhead S; Saffitz JE; Huddleston CB; Spray TL; Canter CE
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1095-101. PubMed ID: 8719456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of the first endomyocardial biopsy in heart transplantation after induction immunosuppressive therapy--experience from Canadian Heart Transplant Centre.
    Málek F; Kaan A; Straatman L; Cheung A; Gnaszewski A
    Cas Lek Cesk; 2005; 144(8):507-9; discussion 509. PubMed ID: 16173602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement fragment C4d and C3d deposition in pediatric heart recipients with a positive crossmatch.
    Holt DB; Liapis H; Mohanakumar T; Phelan DR; Gandi SK; Huddleston CB; Canter CE
    J Heart Lung Transplant; 2008 Oct; 27(10):1073-8. PubMed ID: 18926396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibody-mediated rejection in heart transplantation.
    Fedrigo M; Gambino A; Benazzi E; Poli F; Frigo AC; Tona F; Caforio AL; Castellani C; Toscano G; Feltrin G; Gerosa G; Thiene G; Angelini A
    J Heart Lung Transplant; 2011 Dec; 30(12):1381-8. PubMed ID: 21930398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
    Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
    J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.